Q
Qingdao Xingsai Biotechnology
A developer of single-cell analysis instruments and supporting reagents and consumables
About Qingdao Xingsai Biotechnology
Established in 2014 and headquartered in Qingdao, China, Qingdao Xingsai Biotechnology Co., Ltd. operates within the biotechnology and medical device sectors, specializing in single-cell analysis. The company's revenue model is centered on the development and sale of scientific instruments, associated software, and reagent consumables. Their offerings provide solutions for metabolic phenome-based single-cell imaging, sorting, sequencing, and culture.
The company's product portfolio is segmented into instruments, kits & chips, and software. Key instruments include the FlowRACS, a high-throughput flow Raman sorter; the CAST-R for clinical antimicrobial susceptibility testing; and the RACS-Seq for Raman-activated cell sorting and sequencing. Their software suite, comprising RamEX, RamDB, and RamLIS, supports the hardware. These products serve a diverse client base across precision medicine, human and environmental micro-ecology, and bioresource mining.
A significant figure in the company is co-founder Xu Jian, who also serves as the director of the Bioenergy Research Office and the Single Cell Center of the Qingdao Institute of Energy, Chinese Academy of Sciences. The company has secured strategic funding, including a round in April 2024, with investors such as Neovision Capital, Nanjing Gaoke, and Hengxu Capital backing its growth.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Open positions
- None listed
- Dealroom signal
- 21.3/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- B2B
- Links
- Website
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Jan 2026 | $14M | $55M | Zheshang Capital · Shandong Caijin Venture Capital | ↗ |
| EARLY VC✓Equity / VC | Apr 2024 | $0 | — | Kweichow Moutai | ↗ |
Growth signals
Latest recorded traffic for Qingdao Xingsai Biotechnology is 390 monthly website visits, down 67.5% over the last three months.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Qingdao Xingsai Biotechnology in the Qingdao ecosystem
The Qingdao Xingsai Biotechnology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
- NCNeovision Capital
Series A5 investors entered at this stage
Hengxu Capital- BFBeiyang Haitang Fund
Kweichow Moutai- ZCZheshang Capital
- SCShandong Caijin Venture Capital
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Qingdao Xingsai Biotechnology on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Qingdao Xingsai Biotechnology’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.








